Hikma Pharmaceuticals Plc (LON:HIK) had its price target reduced by J P Morgan Chase & Co from GBX 1,500 ($19.90) to GBX 1,250 ($16.58) in a research note released on Friday. J P Morgan Chase & Co currently has a neutral rating on the stock.

Several other research firms also recently issued reports on HIK. Citigroup Inc. reaffirmed a neutral rating and set a GBX 1,350 ($17.91) price objective on shares of Hikma Pharmaceuticals Plc in a report on Thursday, August 24th. Barclays PLC reaffirmed an overweight rating and set a GBX 2,200 ($29.18) price objective on shares of Hikma Pharmaceuticals Plc in a report on Monday, July 3rd. Peel Hunt reaffirmed a hold rating and set a GBX 2,150 ($28.52) price objective on shares of Hikma Pharmaceuticals Plc in a report on Thursday, August 17th. Stifel Nicolaus downgraded Hikma Pharmaceuticals Plc to a hold rating and reduced their price objective for the stock from GBX 2,300 ($30.51) to GBX 1,320 ($17.51) in a report on Tuesday, August 29th. Finally, Numis Securities Ltd reaffirmed an add rating and set a GBX 1,560 ($20.69) price objective on shares of Hikma Pharmaceuticals Plc in a report on Friday, August 11th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and two have given a buy rating to the stock. Hikma Pharmaceuticals Plc currently has a consensus rating of Hold and an average price target of GBX 1,551.45 ($20.58).

Hikma Pharmaceuticals Plc (LON:HIK) opened at 1207.00 on Friday. The firm’s market capitalization is GBX 2.90 billion. Hikma Pharmaceuticals Plc has a 12 month low of GBX 1,101.00 and a 12 month high of GBX 2,346.00. The stock’s 50 day moving average price is GBX 1,197.59 and its 200 day moving average price is GBX 1,551.40.

TRADEMARK VIOLATION NOTICE: “J P Morgan Chase & Co Cuts Hikma Pharmaceuticals Plc (HIK) Price Target to GBX 1,250” was first posted by Daily Political and is owned by of Daily Political. If you are reading this piece on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The original version of this piece can be read at https://www.dailypolitical.com/2017/10/09/j-p-morgan-chase-co-cuts-hikma-pharmaceuticals-plc-hik-price-target-to-gbx-1250.html.

Hikma Pharmaceuticals Plc Company Profile

Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company’s segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products across the Middle East and North Africa (MENA) region and other markets.

Analyst Recommendations for Hikma Pharmaceuticals Plc (LON:HIK)

Receive News & Ratings for Hikma Pharmaceuticals Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals Plc and related companies with MarketBeat.com's FREE daily email newsletter.